LIXT
insider transactionsLIXTE BIOTECHNOLOGY HOLDINGS, INC. — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
No open-market buys or sells this period. The trades below are grants, option exercises and gifts, which carry no market price.
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Grant·A
Director
$0
25.0K sh
Own New
-
Other·D
Peter Stazzone KEY
Chief Financial Officer
—
50.0K sh
Own -100%
-
Grant·A
Peter Stazzone KEY
Chief Financial Officer
—
50.0K sh
Own New
-
Other·D
Director
—
25.0K sh
Own -100%
-
Grant·A
Director
—
25.0K sh
Own New
-
Other·D
CEO and Chairman of the Board
—
350.0K sh
Own -100%
-
Grant·A
CEO and Chairman of the Board
—
350.0K sh
Own New
-
Other·D
Director
—
25.0K sh
Own -100%
-
Grant·A
Director
—
25.0K sh
Own New
-
Other·D
Director
—
25.0K sh
Own -100%
-
Grant·A
Director
—
25.0K sh
Own New
-
Other·D
Director
—
25.0K sh
Own -100%
-
Grant·A
Director
—
25.0K sh
Own New
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| May 29, 2026 | Stuart D Porter | Grant A | 25.0K | $0 |
| Apr 15, 2026 | Peter Stazzone KEY | Other D | 50.0K | — |
| Apr 15, 2026 | Peter Stazzone KEY | Grant A | 50.0K | — |
| Apr 15, 2026 | Jason David Sawyer | Other D | 25.0K | — |
| Apr 15, 2026 | Jason David Sawyer | Grant A | 25.0K | — |
| Apr 15, 2026 | Geordan Garrett Pursglove KEY | Other D | 350.0K | — |
| Apr 15, 2026 | Geordan Garrett Pursglove KEY | Grant A | 350.0K | — |
| Apr 15, 2026 | Guy Warren Primus | Other D | 25.0K | — |
| Apr 15, 2026 | Guy Warren Primus | Grant A | 25.0K | — |
| Apr 15, 2026 | Michael Andrew Holloway | Other D | 25.0K | — |
| Apr 15, 2026 | Michael Andrew Holloway | Grant A | 25.0K | — |
| Apr 15, 2026 | Lourdes Felix | Other D | 25.0K | — |
| Apr 15, 2026 | Lourdes Felix | Grant A | 25.0K | — |
About LIXT insider trading
This page tracks insider transactions for LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.